Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Clinical trial NCT04364048 · TERMINATED
Trial details
- NCT number
- NCT04364048
- Sponsor
- Rachel Sanborn
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-18
- Primary completion
- 2023-06-20
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.